Luminescence of favipiravir in skin appendages and sclera. A controlled study and literature review

Author:

Demircioğlu Deniz1ORCID,Durmaz Emel Öztürk1ORCID

Affiliation:

1. Department of Dermatology Acıbadem Mehmet Ali Aydınlar University School of Medicine Istanbul Turkey

Abstract

AbstractBackground/ObjectivesFavipiravir is an antiviral agent, recently used for COVID‐19 infections. Several reports associate favipiravir intake with Wood's lamp fluorescence of hair, nails, and sclera. The present study was designed to elucidate the positivity rates, and sites of favipiravir‐related fluorescence and to unravel the site‐specific changes in fluorescence positivity rates by a function of time past exposure.MethodsThe study population comprised 50 patients and 50 control individuals. All patients in the patient group had received a full dose of favipiravir for COVID‐19 infection. Fifty volunteers served as the control group. Wood's lamp examination was performed in a completely darkened room, and the positivity rate, extent, pattern, and distribution of fluorescence were recorded.ResultsWood's light revealed fluorescence of the fingernails, toenails, sclera, and hair in 35 (70%), 35 (70%), 22 (44%), and 8 (16%) patients, respectively. No control individual tested positive by Wood's lamp. Statistical analysis revealed significant differences between patient and control groups in terms of Wood's light luminescence in the fingernails (p = .000), toenails (p = .000), sclera (p = .000) and hair (p = .003). Although fingernail, toenail, and hair fluorescence positivity rates declined or ceased at or after 91 days of favipiravir exposure, ocular fluorescence positivity rates were prolonged up to 188 days.ConclusionsThese findings confirm that favipiravir may produce fluorescence of nails, sclera, and hair, detectable by Wood's light starting from the initial month and peaking at second‐ and third months following exposure to the medication. Although nail and hair fluorescence tend to abate after 3 months, ocular fluorescence may persist even longer than 6 months after cessation of the medication.

Publisher

Wiley

Subject

Dermatology,Radiology, Nuclear Medicine and imaging,Immunology,General Medicine,Immunology and Allergy

Reference27 articles.

1. Favipiravir use for SARS CoV-2 infection

2. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist

3. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies

4. Fluorescence in the sclera, nails, and teeth secondary to Favipiravir use for COVID‐19 infections;Durmaz EÖ;J Clin Aesthet Dermatol,2022

5. Newsbeezer.The truth was spread as an “alternative to the corona test”. Accessed October 2023.https://newsbeezer.com/turkeyeng/the‐truth‐was‐spread‐as‐an‐alternative‐to‐the‐corona‐test/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3